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A recent Phase 3 study of newly diagnosed glioblastoma (GBM) demonstrated the addition of tumor
treating fields (TTFields) to temozolomide (TMZ) after combined radiation/TMZ significantly increased
survival and progression free survival. Preliminary data suggested benefit with both methylated and
unmethylated O-6-methylguanine-DNA methyl-transferase (MGMT) promoter status. To date, however,
there have been no studies to address the potential interactions of TTFields and TMZ. Thus, the effects of
TTFields and TMZ were studied in vitro using patient-derived GBM stem-like cells (GSCs) including
MGMT expressing (TMZ resistant: 12.1 and 22 GSC) and non-MGMT expressing (TMZ sensitive: 33 and
114 GSC) lines. Dose-response curves were constructed using cell proliferation and sphere-forming
assays. Results demonstrated a P10-fold increase in TMZ resistance of MGMT-expressing (12.1 GSCs:
IC50 = 160 lM; 22 GSCs: IC50 = 44 lM) compared to MGMT non-expressing (33 GSCs: IC50 = 1.5 lM;
114 GSCs: IC50 = 5.2 lM) lines. TTFields inhibited 12.1 GSC proliferation at all tested doses (50–
500 kHz) with an optimal frequency of 200 kHz. At 200 kHz, TTFields inhibited proliferation and tumor
sphere formation of both MGMT GSC subtypes at comparable levels (12.1 GSC: 74 ± 2.9% and 38 ± 3.2%,
respectively; 22 GSC: 61 ± 11% and 38 ± 2.6%, respectively; 33 GSC: 56 ± 9.5% and 60 ± 7.1%, respectively;
114 GSC: 79 ± 3.5% and 41 ± 4.3%, respectively). In combination, TTFields (200 kHz) and TMZ showed an
additive anti-neoplastic effect with equal efficacy for TTFields in both cell types (i.e., ± MGMT expression)
with no effect on TMZ resistance. This is the first demonstration of the effects of TTFields on cancer stem
cells. The expansion of such studies may have clinical implications.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2005, Stupp et al. defined the standard of care for newly diag-
nosed glioblastoma (GBM) after maximal surgery as temozolomide
(TMZ) combined with radiation, followed by a post-radiation ‘adju-
vant’ phase of temozolomide administration [1]. First reported by
Hegi et al. MGMT promoter methylation in GBM patients is now
well established as a positive prognostic factor, and a marker for
sensitivity and benefit for TMZ administration [2]. Methylation ofMGMT promoters inhibits MGMT expression, thereby enhancing
tumor sensitivity to TMZ; whereas unmethylated MGMT promot-
ers permit MGMT expression and lead to relative tumor resistance
to TMZ [2,3]. What is now less defined is the benefit of TMZ to
patients with unmethylated MGMT tumors. Until recently, it was
common clinical practice to offer TMZ to unmethylated MGMT
promoter status GBM patients because a reported 8% of this
patient cohort survived long term at 5 years [4]. In the past two
years, however, the value of TMZ in GBM patients with unmethy-
lated MGMT promoter has come into question due to the recogni-
tion of false negative MGMT evaluation (e.g., GBM falsely classified
as unmethylated MGMT status are actually MGMT methylated and
TMZ sensitive) [5,6]. Indeed, since there is low perceived TMZ ben-
efit and an overall poor prognosis for the vast majority of the
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clinical trials of therapies for MGMT-unmethylated GBM patients
[7,8].
Since that advance, a new technology which delivers alternating
low intensity, intermediate-frequency, tumor-treating electric
fields (TTFields) to the patients’ brain via noninvasive transducer
arrays attached to the scalp has been developed and introduced
into GBM clinical practice [9]. The preclinical rationale is TTFields’
ability to inhibit cell growth and induce cell death in a wide range
of tumor models [10,11]. Mechanistically, TTFields disrupt mitotic
spindle formation during metaphase-to-anaphase transition and
cause dielectrophoretic movement of charged or polar molecules
and organelles during anaphase and telophase, resulting in mitotic
arrest and apoptosis [12–15]. Other laboratory studies have started
to address the potential interaction between TTFields and
chemotherapy [16,17].
The first approved use of TTFields was for recurrent GBM [18].
More recently, a Phase 3 clinical study demonstrated that addition
of 200 kHz tumor treating fields (TTFields) to adjuvant temozolo-
mide (TMZ) for newly diagnosed glioblastoma (GBM) increases
both progression free survival (PFS) and overall survival (OS)
[19]. On this basis, the U.S. Food and Drug Administration
approved TTFields’ use in newly diagnosed GBM. Preliminary data
(i.e., a Forest Plot) concerning both O-6-methylguanine DNA-
methyltransferase (MGMT) promoter methylated and unmethy-
lated GBM patient cohorts (presented at the American Society of
Clinical Oncology – 2015) suggested benefit in both patient groups
[20].
Testing a positive interaction between TTFields and TMZ is not
readily feasible in the clinical setting. However, there are signifi-
cant clinical implications for the potential interactions between
TTFields and TMZ, particularly for MGMT-unmethylated GBM
patients (as a subset of the overall large cohort of TMZ resistant
GBM). Indeed, Kirson et al. have speculated that TTFields may act
as a TMZ sensitizer and by implication serve to overcome resis-
tance [16]. Therefore, we decided to test the hypothesis that
TTFields might exhibit a synergistic, or supra-additive interaction
with TMZ, particularly in MGMT protein-expressing GBM cells that
are resistant to TMZ (modeling MGMT-unmethylated GBM
patients). The in vitro analysis of the effects of TTFields and/or
TMZ on MGMT protein expressing (representing unmethylated
MGMT promotor) and non-expressing (representing methylated
MGMT promoter) patient-derived glioblastoma stem cell lines
are described in this report.2. Materials and methods
2.1. Cell lines and culture
Glioblastoma stem-like cells (GSCs) were derived directly from
patient specimens anonymously obtained from the operating
room, under a protocol approved by the University of Wisconsin-
Madison Health Sciences Institutional Review Board (IRB), in surg-
eries for primary GBM (lines 22, 33, 114) or recurrent GBM (line
12.1). Each cell line was authenticated for stem cell-like properties
by validating self-renewal (sphere formation), expression of stem
cell markers (CD133, nestin), multi-lineage differentiation, and
high efficiency orthotopic in vivo tumor initiation in immunodefi-
cient NOD-SCID mice. Briefly, GSCs were enriched from patient
specimens and cultured under marker neutral conditions as previ-
ously described [21,22]. GSCs were propagated as spheres in sus-
pension culture in serum-free stem cell medium termed
‘Passaging Medium, 200 [PM20: 70% DMEM-high glucose, 30%
Ham’s F12, 1  B27 supplement, 5 lg/ml heparin, 1% antibiotics
and 20 ng/ml each epidermal growth factor (EGF) and basicfibroblast growth factor (bFGF)], and passaged approximately
every 10–21 days by tissue chopping 2 at 200 lm [23]. Cells were
maintained at 37 C with 5% CO2. Patient-derived GSC lines 12.1
(passages 20–35), 22 (passages 25–40), 33 (passages 20–35), and
114 (passages 5–15) were used in this study.
2.2. Cell proliferation assays
GSC spheres were enzymatically dissociated to single cells
using Accutase (Millipore) and counted manually using a hemacy-
tometer. Then 50,000 cells in a 100 ll drop of PM20 medium were
plated on a laminin coated plastic coverslip (Thermanox, Thermo
Fisher Scientific), and placed in a 6-well tissue culture plate. GSCs
were allowed to adhere overnight prior to filling wells with PM20
medium. Coverslips were transferred into ceramic petri dishes
using sterile forceps, and TTFields were applied using the Inovitro
system (Novocure Ltd., Haifa, Israel) [13,24]. Briefly, the Inovitro
system used two pairs of transducer arrays printed perpendicularly
on the outer walls of a petri dish composed of high dielectric con-
stant ceramic [lead magnesium niobate–lead titanate (PMN-PT)].
The transducer arrays were connected to a sinusoidal waveform
generator that generated treating fields at the desired frequencies
ranging from 50 to 500 kHz. The orientation of the TTFields
switched 90 every second, thus covering the majority of the orien-
tation axis of cell divisions, as previously described [10]. For all
experiments, cells were treated with TTFields at approximately
1 V/cm intensity. TTFields experiments were performed in a refrig-
erated incubator (170R Galaxy, New Brunswick) set at 18 C to dis-
sipate heat generated by TTFields administration, while cells were
maintained at 37 C by Inovitro system using feedback from 2 ther-
mistors (Omega Engineering, Stamford, CT) attached to the ceramic
walls. TTFields were applied for 8 days, determined as optimal
duration from preliminary GSC proliferation curve experiments
(data not shown). Culture medium was replaced daily. At the end
of experiments, GSCs were enzymatically detached using Accutase
and manually counted using a hemacytometer.
Parallel TMZ dose–response experiments were performed in
12-well tissue culture dishes (Corning) coated with laminin. Pre-
liminary experiments verified no difference in GSC proliferation
rate between coverslips and tissue culture dishes (data not shown).
2.3. GSC sphere-forming assays
Plating densities resulting in visible, near-clonogenic sphere
proliferation for 12.1, 22, 33, and 114 GSC lines were first opti-
mized. To establish TMZ dose response curves, GSC spheres were
enzymatically dissociated to single cells and re-plated in 96-well
plates at optimal density (500–1000 cells) in PM20 medium. After
recovery overnight, test TMZ doses or vehicle control (0.1% DMSO)
was added to establish a dose–response curve. Upon formation of
200 lm diameter spheres in control groups (2–4 weeks), the total
number of tumor spheres was manually counted in each culture
well. The relative 50% inhibitory concentrations (IC50) of temozolo-
mide were calculated from sphere-forming assays by 4-parameter
logistic model [25].
For TTFields experiments, GSCs were assayed for proliferation
as described above after exposure to TTFields ± TMZ, enzymatically
removed from coverslips, and live cells re-plated at optimal density
in PM20 medium for sphere-forming assay. No additional TTFields
or TMZ were administered.
2.4. MGMT RT-PCR
Expression of the MGMT DNA repair enzyme was analyzed
in GSCs using reverse transcription polymerase chain reaction
(RT-PCR). RNA was isolated from stably growing GSCs, per
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created from 1 lg RNA using reverse transcription for 1 h at
37 C (Omniscript RT kit, Qiagen) with oligo(dT) primers
(Oligo(dT)12–18 primer, Invitrogen/Life Technologies). PCR was then
performed (Taq PCR Kit, Qiagen) for MGMT, with GAPDH as loading
control, using specific primers: MGMT: F, 50-GGA GGC ACC GCT
GTA TTA AA-30 and R, 50-GCA GGT AGG AAA CAA AGC TAG A-30,
product size 483 bp; GAPDH: F, 50-ACC ACAGTC CAT GCC ATC
AC-30 and R, 50-TCC ACC ACC CTG TTG CTG TA-30, product size
452 bp. PCR thermocycling parameters included initial denatura-
tion for 3 min at 94 C; 30 total cycles of denaturation 1 min at
94 C, annealing for 1 min at 55 C, extension for 1 min at 72 C;
and a final extension step of 7 min at 72 C. PCR products were
then combined with loading buffer (Promega) and electrophoresed
in a 2% agarose gel (Agarose-HR, Ambion) containing 1 lg/ml
ethidium bromide. Finally, DNA bands were visualized using an
automated imaging system set to image 600 nm wavelength
(Odyssey Fc, LI-COR Biosciences). Product sizes were verified using
a known molecular weight ladder run in parallel (exACTGene Low
Range DNA ladder, Fisher Scientific).
2.5. Statistical analysis
The data were expressed as mean ± standard error mean (SEM).
Statistical analysis was performed with Statistical Product and Ser-
vice Solutions (SPSS version 22, IBM). Two sample comparisons
were made using student T-tests. Group comparisons were made
using analysis of variance (ANOVA) after verification of normal dis-
tribution, followed by post hoc Tukey tests. The criterion for statis-
tical significance was chosen as p < 0.05.3. Results
3.1. Patient-derived GSCs vary in MGMT expression and temozolomide
sensitivity
Patient-derived GSC lines were analyzed for MGMT expression
using RT-PCR. MGMT RNA expression was detected in 12.1 and
22 GSCs, but was absent/minimal in 33 and 114 GSCs (Fig. 1A).
The effect of temozolomide on the multiple patient-derived GSC
lines was then tested, and differential GSC responses (sensitivity/
resistance) corresponding to MGMT expression were observed
(Fig. 1B, nP 3 independent experimental replicates). The IC50 for
each cell line was derived:12.1 GSC = 160 lM, 22 GSC = 44 lM,
33 GSC = 1.5 lM, and 114 GSC = 5.2 lM. Thus, as expected, theFig. 1. (A). MGMT expression in patient-derived glioblastoma stem-like cell (GSC) lines d
response curves for GSC lines (mean ± S.E., nP 3 independent experiments). In a tumor
TMZ (IC50 = 160 lM and 44 lM, respectively) compared to non-MGMT-expressing 33 anMGMT-expressing 12.1 and 22 GSC lines (which would clinically
correspond to unmethylated MGMT GBM) were relatively resistant
to TMZ, and the 33 and 114 GSC lines that do not express MGMT
(which would clinically correspond to methylated MGMT GBM)
were relatively sensitive to TMZ.
3.2. TTFields inhibition of GSC proliferation
The response of GSCs to TTFields was then analyzed and a fre-
quency response curve was constructed using 12.1 GSCs. This anal-
ysis demonstrated maximal GSC proliferation inhibition at 200 kHz
TTFields (Fig. 2A, nP 3 independent experimental replicates).
TTFields effects on 12.1 and 22 GSC lines (TMZ resistant) and 33
and 114 GSC lines (TMZ sensitive) were determined. Using
200 kHz TTFields, significant GSC proliferation and sphere forma-
tion inhibition were measured (Figs. 2B, 2C; nP 3 independent
experimental replicates, p < 0.05). Cell proliferation inhibition
(mean ± S.E.) by TTFields was similar among 12.1 GSCs
(74 ± 2.9%), 22 GSCs (61 ± 11%,), 33 GSCs (56 ± 9.5%), and 114 GSCs
(79 ± 3.5%). Tumor sphere formation (mean ± S.E.) was also inhib-
ited similarly among 12.1 GSCs (38 ± 3.2%,), 22 GSCs (38 ± 2.6%),
33 GSCs (60 ± 7.1%), and 114 GSCs (41 ± 4.3%).
3.3. TTFields provide additive effect when combined with TMZ
Combination studies to examine interactions between TTFields
and TMZ were also performed. The addition of 200 kHz TTFields
provided additional inhibitory effects at all doses of TMZ tested
for both cell proliferation and sphere-formation of 12.1 and
22 GSCs (MGMT expressing) (Fig. 3A, nP 3 independent experi-
mental replicates) and 33 and 114 GSCs (non-MGMT expressing)
(Fig. 3B, nP 3 independent experimental replicates). Equal slopes
of TMZ dose response curves with and without 200 kHz TTFields
suggested an additive, but not supra-additive or synergistic effect
resulting from combining the two treatments.4. Discussion
The introduction of TTFields to the treatment of newly diag-
nosed GBM represents the first significant advance since the intro-
duction of TMZ in 2005 [1]. The apparent clinical efficacy in both
methylated and unmethylated MGMT promoter GBM [19,26] led
to the American Food and Drug Administration approval for the
use of TTFields specifically in conjunction with adjuvant TMZ. It
is also notable that newly released 2016 National Comprehensiveetermined by RT-PCR. GAPDH RT-PCR serves as RNA loading control. (B) TMZ dose–
sphere forming assay, MGMT expressing 12.1 and 22 GSCs are relatively resistant to
d 114 GSCs (IC50 = 1.5 lM and 5.2 lM, respectively).
Fig. 2. Tumor-treating Fields (TTFields) inhibit GSC proliferation and tumor sphere formation. Frequency–response plot of GSCs treated with TTFields show optimal inhibition
at 200 kHz (A), mean ± S.E., nP 3 independent experimental replicates. TTFields at 200 kHz (gray bars) significantly inhibited cell proliferation (B) and tumor sphere
formation (C) compared to untreated controls (white bars) in both MGMT-expressing 12.1 and 22 GSCs (TMZ resistant) and non-MGMT-expressing 33 and 114 GSCs (TMZ
sensitive) (mean ± S.E., nP 3 independent experimental replicates, ⁄p < 0.05 compared to no TTFields by Student’s t-test).
Fig. 3. Anti-neoplastic effects of TTFields and TMZ were additive. In MGMT expressing (TMZ resistant) (A) and non-MGMT expressing (TMZ sensitive) (B) GSCs, additional
treatment with 200 kHz TTFields inhibited cell proliferation and sphere formation more than TMZ alone, at all tested doses (mean ± S.E., nP 3 independent experimental
replicates).
P.A. Clark et al. / Journal of Clinical Neuroscience 36 (2017) 120–124 123Cancer Network (NCCN) revised guidelines, recognizing the signif-
icance of TMZ resistance in non-methylated GBM patient’s, offers
the option of radiation treatment only (which is not a stated option
for MGMT methylated GBM cohorts) versus radiation with TMZ
with or without TTFields. However, radiation alone with TTFields
is not an option even in a non-methalyated MGMT patient popula-
tion. What is not clear from the clinical data now available, how-
ever, is whether there is an interaction between TTFields and
TMZ. An important corollary question is whether adjuvant TMZ
is necessary to elicit the full benefit of TTFields in non-
methylated MGMT GBM patients.
To address this question preclinically, patient-derived GSCs
were chosen for in vitro studies on the basis of their highly efficient
tumor initiation capacity and evidence that they are more geneti-
cally similar to in vivo patient GBM and applicable for clinically
useful biomarker discovery [22,27–29]. To the best of our knowl-
edge this is the first study to report the effects of TTFields on cancer
stem cells. The results presented here demonstrate equal efficacy
for TTFields in both types of GBM cells (both ± MGMT expression),
consistent with the reported observation of clinical benefit in both
patient populations. There was no indication of an interaction with
TMZ. A possible clinical implication of these data is that adjuvant
treatment omitting TMZ and only using TTFields therapy post radi-
ation is predicted to be efficacious against GBMs with unmethy-
lated MGMT promoters.Interestingly, the optimal 200 kHz frequency for TTFields inhi-
bition (hypothesized to partly depend on tumor cell size) that
was empirically determined in our study, is also the clinically used
frequency for treating GBM patients [19]. It is also notable that our
studies demonstrate the existence of two separate frequencies
leading to maximal response, i.e., 200 kHz and 500 kHz (Fig. 2).
There are two physical phenomena which underlie the effect of
TTFields: dielectrophoresis which occurs mainly during cytokine-
sis, and dipole alignment. Electric field simulations have demon-
strated that the frequencies expected to cause maximal
dielectrophoretic forces during cytokinesis are within the range
of 100–200 kHz, while the maximal effect on dipole alignment is
expected to appear at higher frequencies (towards 1 MHz) [30]. It
is therefore possible that the biphasic nature of the observed
response is the outcome of dielectrophoresis induced at 200 kHz,
and dipole alignment occurring at higher frequencies. An alterna-
tive explanation could be the result of heterogeneous cancer stem
cell plasticity and aberrant differentiation resulting in multiple
populations with different characteristics. It is possible that the
different GSC populations are susceptible to the effects of two dis-
tinct frequencies, and that the biphasic response is the cumulative
effects on the different cells.
Our studies demonstrating a lack of supra-additive or synergis-
tic effect in combining TTFields with TMZ against GSC of either
MGMT status were not entirely unexpected. Mechanistically,
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polymerization by generating non-uniform intracellular fields that
exert forces that move polar macromolecules and organelles,
resulting in apoptosis driven cell death [11]. In contrast, TMZ’s
mechanism of action is based on its ability to alkylate/methylate
DNA rather than disrupting mitosis [2,7]. However, drugs that
interfere with mitosis, e.g., paclitaxel, might be predicted to syner-
gize with TTFields; indeed, preliminary data regarding TTFields
and paclitaxel suggest that possibility [16].
The expansion of these studies has clinical implications specif-
ically for patients with unmethylated GBM. Since the efficacy of
TMZ in MGMT unmethylated patients is considered by many to
be minimal [5–7] (possibly reflecting inadequate MGMT marker
testing), clinical researchers may consider testing TTFields in com-
bination with other agents as adjuvant GBM therapy. We are now
performing additional preclinical investigations with TTFields that
include assessment of TTFields’ effects on additional patient-
derived tumor lines derived from GBM and other cancers. Analysis
of the potential interactions in combining ionizing irradiation and
TTFields, and/or blood brain barrier-permeable drugs that might
mechanistically synergize with TTFields (e.g., inhibit mitosis) are
also in progress. In summary, our in vitro data does not provide evi-
dence for combining TTFields therapy with TMZ in unmethylated
GBM patients, but does support the use of TTFields alone as adju-
vant therapy in this patient subset. This work highlights the need
for continued laboratory and clinical research for this unique and
emerging therapy.
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